Marina Biotech this week said that the US Patent and Trademark Office has issued a notice of allowance for three of the company's patent applications related to its delivery technologies.
The European Patent Office has also said it will grant the company a patent on a related technology, Marina said.
According to the company, the USPTO patent applications relate to the Smarticle amphoteric-based liposomal delivery vehicles Marina acquired from Novosom in 2010. The EPO application covers its DiLA2 amino acid-based liposomal delivery system.